Key result
Adding BMS-986141 to apixaban reduces ex vivo thrombus area by ~11%, especially under high shear.
Why the study?
The additive antithrombotic activity of PAR4 antagonism combined with factor Xa inhibition under conditions of acute arterial injury was not established.
Does combined PAR4 antagonism and factor Xa inhibition reduce thrombus formation in an ex vivo model of acute arterial injury in healthy volunteers?
Comparison
BMS-986141 with low-dose or high-dose apixaban vs vehicle, apixaban alone, or BMS-986141 alone
Design
Phase zero double-blind randomized controlled crossover trial
Authors
Loading...
PAR4 antagonism may add modest antithrombotic effect to factor Xa inhibition under high shear; extends ex vivo RCT evidence but requires clinical outcome trials.
RCT (n=15)
Double-blind
crossover
Does combined PAR4 antagonism and factor Xa inhibition reduce thrombus formation in an ex vivo model of acute arterial injury in healthy volunteers?
p-value: p=≤0.027
Combined PAR4 antagonism and factor Xa inhibition provides additive reduction in thrombus formation under high shear stress in an ex vivo model, suggesting potential for atherothrombotic event prevention.
Meah et al. (2020) conducted an RCT in healthy volunteers (n=15). BMS-986141 combined with apixaban vs. vehicle, BMS-986141 alone, or apixaban alone was evaluated on Total thrombus area (p=≤0.027). Combining the PAR4 antagonist BMS-986141 with apixaban further reduced total thrombus area by 9.6%–12.4% in an ex vivo model, especially under high shear stress conditions (P≤0.027).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: